Two Sigma Advisers
CERE

Two Sigma Advisers’s Cerevel Therapeutics Holdings, Inc. Common Stock CERE Stock Holding History

Two Sigma Advisers’s Portfolio CERE Stock Details CERE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-101,700
Closed -$4.16M – 2590
2024
Q2 		$4.16M Buy
101,700
+58,900
+138% +$2.45M 0.01% 845
2024
Q1 		$1.81M Buy
+42,800
New +$1.8M ﹤0.01% 1283

Other funds holding CERE

IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
BTI
Blue Trust Inc Alpharetta, Georgia $8.74B AUM 14.62% 1-Year Est. Return

Two Sigma Advisers's CERE Position: Q3 2024 in Review

Two Sigma Advisers sold out of Cerevel Therapeutics Holdings, Inc. Common Stock (CERE) in Q3 2024, closing a stake of 101,700 shares — an estimated $4.16M sold.

Two Sigma Advisers first reported a position in CERE in Q1 2024 and held it in 2 quarters. The position peaked at $4.16M in Q2 2024. 2 funds tracked by Wall St. Rank hold CERE as of Q3 2024.

  • Two Sigma Advisers reported no remaining Cerevel Therapeutics Holdings, Inc. Common Stock position as of Q3 2024 after selling out during the quarter.
  • Two Sigma Advisers sold 101,700 Cerevel Therapeutics Holdings, Inc. Common Stock shares in Q3 2024, an estimated $4.16M.
  • Two Sigma Advisers first reported a position in Cerevel Therapeutics Holdings, Inc. Common Stock in Q1 2024 and held it in 2 quarters.
  • Two Sigma Advisers's Cerevel Therapeutics Holdings, Inc. Common Stock position peaked at $4.16M in Q2 2024.
  • 2 funds tracked by Wall St. Rank held Cerevel Therapeutics Holdings, Inc. Common Stock as of Q3 2024.

Based on Two Sigma Advisers's 13F filing for Q3 2024, filed 14 Nov 2024.